Categories Earnings, Health Care

Earnings preview: What to expect when Allergan reports Q1 2019 earnings results

Allergan plc (NYSE: AGN) is scheduled to report earnings results for the first quarter of 2019 on Tuesday, May 7, before market open. Revenue is expected to decline 3.9% year-over-year to $3.53 billion while EPS is expected to fall 5.1% to $3.55.

The company has consistently topped earnings estimates over the past four quarters and can be expected to do the same for the first quarter as well.

In the first quarter, Allergan’s revenues are likely to be fueled by its key products such as Botox, Juvederm, Vraylar, Linzess and Lo Loestrin. Allergan has new product launches coming this year, including Cariprazine, which provide opportunities for further growth.

A number of competitors have launched new products over the past year and how these products have impacted the demand for Allergan’s products is a point to look for during the results announcement. Updates on the company’s recent progress with regards to its pipeline is also an area to watch.

In March, Allergan acquired a privately held company called Envy Medical Inc. The acquisition is expected to boost Allergan’s Medical Aesthetics portfolio through the addition of Envy’s skin resurfacing treatment Dermalinfusion. Updates on this deal can be expected.

Meanwhile, Allergan’s revenue could face negative impacts from a couple of factors such as loss of exclusivity, generic competition and pricing pressures. Revenue might also take a hit from the Ozurdex breast implant recalls.

In the fourth quarter of 2018, Allergan’s revenue and earnings surpassed expectations despite seeing year-over-year declines. Total revenues declined 5.7% to $4.08 billion while adjusted EPS dropped 11.7% to $4.29.

Also Read:  Infographic: Highlights of Gilead Sciences (GILD) Q3 earnings report
Allergan fourth quarter 2018 earnings infographic
Allergan Q4 2018 Earnings Infographic

Allergan’s shares have gained 10% so far this year.

On Thursday, Allergan’s rival Teva Pharmaceutical (NYSE: TEVA) reported its first quarter 2019 earnings, in which earnings topped estimates while revenues fell short.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Starbucks (SBUX) stock falls after Q4 earnings

Starbucks (NASDAQ: SBUX) reported fourth-quarter 2020 financial results after the closing bell on Thursday. The coffee chain reported an 8% decline in Q4 revenues to $6.20 billion, which was better

Facebook reports stellar results in Q3

Facebook (NASDAQ: FB) reported third-quarter 2020 financial results after the closing bell on Thursday. The social media giant reported a 22% spike in Q3 revenue to $21.47 billion, which was

AMZN Earnings: All you need to know about Amazon Q3 2020 earnings results

Amazon.com, Inc. (NASDAQ: AMZN) reported third quarter 2020 earnings results today. Net sales increased 37% year-over-year to $96.1 billion. Net income increased to $6.3 billion, or $12.37 per share, from

Top